Cencora医药
COR
340.92
-0.49
-0.14%
Cencora医药
US · COR
#374 按市值排名
上市于 1970
340.92
-0.49
-0.14%
实时 - 追踪5344个代码 - 心跳于465秒前
· 2026-10-16 19:30
最新新闻
-
评级变动
BofA Securities Maintains Cencora(COR.US) With Hold Rating\u5e02\u573a\u8d44\u8baf · 2026/8/1
-
评级变动
TD Cowen Maintains Cencora(COR.US) With Buy Rating, Maintains Target Price $400\u5e02\u573a\u8d44\u8baf · 2026/8/10
-
评级变动
J.P. Morgan Maintains Cencora(COR.US) With Buy Rating, Cuts Target Price to $390\u5e02\u573a\u8d44\u8baf · 2026/8/11
-
公司公告
INTEGRATED RAIL & RESOURCES ACQ COR C/WTS (TO PUR COM) | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Yakira Partners, L.P.(0.00%),MAP 136 Segregated Portfolio(0.00%)SEC · 2024/4/9
-
公司公告
CDJJ INV B2803B: PUBLICATION OF THE OFFERING CIRCULAR - U.S.$100,000,000 4.94 PER CENT. CREDIT ENHANCED SUSTAINABLE BONDS DUE 2028 ISSUED BY CHENGDU JIANJIANG INVESTMENT GROUP CO., LTD. WITH THE BENEFIT OF AN IRREVOCABLE STANDBY LETTER OF CREDIT ISSUED BY HUISHANG BANK CORHKEX · 2025/3/7
-
Morgan Stanley Maintains Cencora(COR.US) With Buy Rating, Raises Target Price to $346\u5e02\u573a\u8d44\u8baf · 2026/8/7
-
Wells Fargo Maintains Cencora(COR.US) With Buy Rating, Raises Target Price to $395\u5e02\u573a\u8d44\u8baf · 2026/8/11
-
评级变动
Ping An (601318) Commentary: Profit growth exceeded expectations; OPAT, NBV, and COR were in line with forecasts.Shenwan Hongyuan Research · 2026/8/21
-
公司公告
INTEGRATED RAIL & RESOURCES ACQ COR UNIT 1 COM CL A & 1/2 WT EXP | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Yakira Partners, L.P.(0.00%),MAP 136 Segregated Portfolio(0.00%)SEC · 2024/4/9
-
评级变动
A Quick Look at Today's Ratings for Cencora(COR.US), With a Forecast Between $350 to $430\u5e02\u573a\u8d44\u8baf · 2026/8/6
-
评级变动
J.P. Morgan Sticks to Their Buy Rating for Cencora (COR)TipRanks · 2026/8/11
-
RBC Capital Maintains Cencora(COR.US) With Hold Rating, Maintains Target Price $330\u5e02\u573a\u8d44\u8baf · 2026/10/7
-
公司公告
INTERNATIONAL MEDIA ACQUISITION COR COM USD0.0001 (SUB/RGT) | 8-K: Current reportSEC · 2024/4/9
-
评级变动
Barclays Maintains Cencora(COR.US) With Buy Rating, Maintains Target Price $350\u5e02\u573a\u8d44\u8baf · 2026/8/14
-
评级变动
A Quick Look at Today's Ratings for Cencora(COR.US), With a Forecast Between $346 to $430\u5e02\u573a\u8d44\u8baf · 2026/8/7
-
China Taiping Insurance (601601) 2026 Interim Report Commentary: Life insurance NBV benefits from improved value margin, while property insurance COR has improved markedly.Huachuang Securities · 2026/8/27
-
公司公告
INTERNATIONAL MEDIA ACQUISITION COR COM USD0.0001 (SUB/RGT) | 8-K: Current reportSEC · 2024/3/8
-
评级变动
RBC Capital Initiates Cencora(COR.US) With Hold Rating, Announces Target Price $330\u5e02\u573a\u8d44\u8baf · 2026/8/19
-
评级变动
Evercore Maintains Cencora(COR.US) With Buy Rating, Maintains Target Price $350\u5e02\u573a\u8d44\u8baf · 2026/8/13
-
Cencora(COR.US) Officer Sells US$3.66 Million in Common Stock\u5e02\u573a\u8d44\u8baf · 2026/8/26
-
评级变动
BofA Securities Maintains Cencora(COR.US) With Hold Rating, Announces Target Price $310\u5e02\u573a\u8d44\u8baf · 2026/7/22
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
Cencora医药 讨论区 0 条评论